Milford-based Waters Corp. reported third-quarter revenue of $1.767 billion, including $871 million of organic revenue and $896 million of revenue from the acquired Biosciences and Diagnostic Solutions divisions.
Organic revenue for the third quarter of 2026 was $871 million, up from $800 million in the third quarter of 2025, an increase of 9% reported and 10% in constant currency, according to a statement from Waters Corp.
The $896 million in revenue from Biosciences and Diagnostic Solutions for the third quarter of 2026 compares to $885 million for the same quarter last year.
Waters Corp. develops analytical instruments used in drug development, food safety testing and environmental analysis. Researchers use its products to bring new drugs and diagnostic tools to market, supporting a range of scientific and industrial applications.
The company reported diluted earnings of $0.82 per share for the third quarter of 2026, compared to diluted earnings per share of $2.50 for the third quarter of 2025, reflecting acquisition-related purchase accounting charges, acquisition-related costs and restructuring costs.
“Our team delivered exceptional results led by best-in-class consumables growth across both our Analytical Sciences and Biosciences divisions, as strong execution, new product innovation, and rising customer testing volume accelerated growth,” said Udit Batra, president and CEO of Waters Corp.
The company is raising its acquired business revenue expectations and now expects full-year 2026 acquired business reported revenue of approximately $3.050 billion on an owned-period basis. Total company reported revenue for full-year 2026 is expected to be in the range of $6.479 billion to $6.497 billion, Waters reported.
Waters is updating its full-year 2026 adjusted earnings per share guidance to the range of $14.60 to $14.70, which represents 11% to 12% year-over-year adjusted EPS growth and is 13% to 14% on a constant currency basis.
Founded in 1958, Waters employs about 1,300people in Central Massachusetts and 16,000 worldwide. It is the seventh-largest life sciences company in Central Massachusetts and the 10th-largest manufacturer in the region, according to data collected by WBJ’s Research Department.